⟵ Back to Search Results

BGB-A317-A1217-203

Completed

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Beigene Study ID info

BGB-A317-A1217-203

ClinicalTrials.gov ID info

NCT04732494

EudraCT Number info

2020-004658-32

China Drug Trials ID info

CTR20213241/CTR20210243

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan